Feature | May 03, 2010| Dave Fornell

Companies Developing Drug-Eluting Balloons

The Paccocath coating of the B.Braun SeQuent Please DEB uses contrast media to separate and evenly distribute the paclitaxel molecules over the surface of the balloon. The anti-proliferative drug helps prevent restenosis.

The Paccocath coating of the B.Braun SeQuent Please DEB uses contrast media to separate and evenly distribute the paclitaxel molecules over the surface of the balloon. The anti-proliferative drug helps prevent restenosis.

Several paclitaxel drug-eluting balloons (DEBs) are currently available on the European market, and several others are in development. There are currently no DEBs available in the United States.

In 2009, Invatec launched four DEBs in Europe. The In.Pact Amphirion is designed to treat atherosclerosis in arteries located below the knee. The In.Pact Admiral targets the superficial femoral arteries. The In.Pact Pacific is a 0.018-inch peripheral DEB. The peripheral products offer a size range from 3 to 7 mm diameters, and balloon lengths ranging from 40 to 120 mm. The In.Pact Falcon also was released for coronary vessels.

Medtronic purchased Invatec earlier this year to expand its offerings in peripheral artery disease (PAD) treatments.

B. Braun introduced its SeQuent Please coronary DEB last year in Europe. It uses the Paccocath balloon coating matrix licensed through Bayer AG.

The Dior DEB made by EuroCor was the first DEB to earn a CE mark clearance in 2007. The drug is embedded in its microporous balloon surface, which elutes during a one-minute balloon expansion. A newer generation balloon uses shellac as a carrier.

Aachen Resonance GmbH offers the Elutax DEB in Europe for coronary and small vessels. It also uses a microporous surface.

The Acrostak Genie catheter drug delivery system has two small balloons at the distal and proximal ends of the device. They are inflated under low pressure and the occluded area is flushed with paclitaxel. After an exposure of two minutes, studies revealed the growth of stenosis is permanently inhibited.

Works in Progress

In January 2009, Micell Technologies entered into an agreement with EuroCor to develop a new generation of DEBs. The specific terms of the agreement were not disclosed, but the deal is likely aimed at creating an improved Dior DEB. Micell has developed a unique bioabsorbable polymer coating that is absorbed concurrently with the drug delivery. The technology allows both the polymer and drug to be eliminated within 90 days.

The Genesis DESA (Drug Eluting Scoring Angioplasty), from Genesis Technologies, uses a nitinol mesh braid over the DEB. The braid is supposed to create microfractures in the plaque for better drug delivery.
In the summer of 2009, Lutonix Inc. began patient enrollment for its three simultaneous first-in-human clinical trials to test its Lutonix drug coated balloon catheter. The PERVIDEO I Registry is investigating the DEB’s use in treating coronary bare metal stent in-stent restenosis. The LEVANT I Trial is examining its use in preventing restenosis in the femoropopliteal arteries. The Lutonix De Novo Pilot Study will assess the interaction between bare metal stents and the DEB.

Medrad’s Cotavance DEB uses the Paccocath balloon coating matrix technology from its parent company, Bayer AG. Medrad has submitted a clinical trial request with the U.S. Food and Drug Administration (FDA) and hopes to begin the trial in late 2010.

Cook Medical is currently in European trials with its Advance PTX drug-eluting balloon.
Boston Scientific said it also is developing a paclitaxel-eluting DEB to treat peripheral vessels.
DSM Biomedical develops both medical device coatings and drug delivery coatings, which it is using to create new DEBs.

Related Content

ACR, American College of Radiology, MEDCAC, peripheral arterial disease, PAD, seniors
News | Peripheral Arterial Disease (PAD)| April 18, 2016
The American College of Radiology (ACR), as a member of a coalition of leading medical societies, provided peripheral...
Corindus, CorPath Robotic System, FDA clearance, peripheral vascular interventions
Technology | Robotic Systems| March 29, 2016
Corindus Vascular Robotics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the CorPath...
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter| March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
PinnacleHealth Cardiovascular Institute, TOBA II study, first patient, Tack Endovascular System, PAD
News | Peripheral Arterial Disease (PAD)| March 22, 2016
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania into the TOBA II clinical on Oct. 19...
Boston Scientific, Eluvia vascular stent system, CE Mark, peripheral artery disease
News | Stents Peripheral| March 17, 2016
Boston Scientific announced in late February that the Eluvia Drug-Eluting Vascular Stent System received CE Mark, and...
PAD, peripheral artery disease, critical limb ischemia, CLI, blood circulation, injectable gel, UC San Diego study
News | Peripheral Arterial Disease (PAD)| March 16, 2016
Bioengineers and physicians at the University of California, San Diego have developed a potential new therapy for...
Avinger, Pantheris lumivascular atherectomy system, PAD treatment, peripheral artery disease, FDA clearance
Technology | Atherectomy Devices| March 03, 2016
Avinger Inc. announced the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...
Intact Vascular, Tack Endovascular System

The Intact Vascular Tack Endovascular System is designed to spot stent dissections with a short, self-expanding 6 mm long stent that can expand to vessel diameters between 2.5-6 mm, so exact sizing is not needed.

Feature | Peripheral Arterial Disease (PAD)| February 22, 2016 | Dave Fornell
It is estimated that more than 10 million people in the United States are affected by...
peripheral stents, market report 2020, MedMarket Diligence
News | Stents Peripheral| February 19, 2016
Peripheral stents will account for over $4.6 billion in worldwide sales by 2020, according to a new report from...
Biotronik, Maquet, partnership, peripheral vascular devices, U.S. market, Astron self-expanding iliac stent
Technology | Stents Peripheral| February 17, 2016
Biotronik announced a partnership with Maquet Medical Systems USA to distribute Biotronik peripheral vascular devices...
Overlay Init